Humanwell Healthcare Group's (SHA:600079) subsidiary, Yichang Humanwell Pharmaceutical, will conduct clinical trials on esketamine hydrochloride injection after receiving the National Medical Products Administration's approval, according to a Shanghai Stock Exchange filing on Thursday.
The antidepressant will be tested as a treatment for depressed patients with acute suicidal ideation or behavior.
The pharmaceutical company invested around 3 million yuan into the research and development of the drug.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。